Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).

This is because the technology is a further treatment option and the overall cost of treatment will be similar.

The company has a commercial arrangement (simple discount patient access scheme). This makes fluocinolone acetonide intravitreal implant available to the NHS with a discount. For enquiries about the patient access scheme please contact chris.wright@alimerasciences.com.

This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.


This page was last updated: